NAD+ Deep-Dive
Also known as: Nicotinamide Adenine Dinucleotide · NAD
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to mitochondrial electron transport, sirtuin activity, and PARP-mediated DNA repair. Researchers investigate exogenous NAD+ administration and its precursors (NMN, NR) as approaches to support cellular NAD+ pools, which decline with age. The compound is investigated in longevity research, mitochondrial-function research, and metabolic applications.
Plasma Half-Life
Variable (minutes for IV NAD+; hours for precursors)
Logarithmic scale · 4 hr mapped
Tissue Residency
Cellular NAD+ pool turnover measured in hours; tissue effects depend on uptake and conversion
Quick Facts
- Typical dose
- 100–500 mg subcutaneous; 250–1000 mg IV; precursor (NMN/NR) protocols 250–1000 mg oral
- Range
- 50 mg – 1500 mg per session depending on route and formulation
- Route
- Subcutaneous, intramuscular, intravenous, intranasal, or oral precursor (NMN, NR). IV protocols typically delivered over 1–4 hours.
- Cycle pattern
- Common practitioner pattern: loading phase of 5–10 IV sessions over 2–4 weeks, then weekly or biweekly maintenance. Subcutaneous protocols often run 3–5 days/week. Oral precursor protocols are typically continuous.
- Primary evidence tier
- Experimental
Mechanism of Action
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to mitochondrial electron transport, sirtuin activity, and PARP-mediated DNA repair. Researchers investigate exogenous NAD+ administration and its precursors (NMN, NR) as approaches to support cellular NAD+ pools, which decline with age. The compound is investigated in longevity research, mitochondrial-function research, and metabolic applications.
Researchers investigate NAD+ in the broader context of the Longevitycompound class. The compound's proposed relationship to underlying physiology is typically framed against the ATP Shortage axis — a framework DoseCraft uses to organize research priorities across the 90+ compound library.
In the practitioner corpus that trains the DoseCraft AI copilot, NAD+'s mechanism is repeatedly cross-referenced against its pharmacokinetic profile (plasma half-life Variable (minutes for IV NAD+; hours for precursors)) because dosing cadence, stack selection, and cycling structure all derive from the PK window. This is the core difference between a static calculator and a PK-aware reasoning layer.
Pharmacokinetics
Plasma Half-Life (Logarithmic)
Variable (minutes for IV NAD+; hours for precursors)
Logarithmic scale · 4 hr mapped
Tissue Residency
Cellular NAD+ pool turnover measured in hours; tissue effects depend on uptake and conversion
NAD+ has a plasma half-life of approximately Variable (minutes for IV NAD+; hours for precursors). This window is the primary driver of every downstream protocol decision: dosing frequency, stack overlap, cycling length, and the observable duration of subjective response.
Beyond the plasma window, cellular nad+ pool turnover measured in hours; tissue effects depend on uptake and conversion. This tissue-residency or functional-duration behavior is why practitioner protocols often deviate from what raw plasma half-life alone would suggest.
In the DoseCraft PK model, this compound is mapped onto the same decay-curve framework that powers the half-life visualizer in the app — every stack built in the Protocol Builder factors in the half-life overlap of NAD+alongside any co-administered compounds. Static calculators elsewhere ignore this; it's why the practitioner corpus consistently flags half-life literacy as a top-three safety variable.
From real clinicians · not PubMed abstracts
Practitioner Protocols
Practitioner Corpus
Sourced from 10,000+ hours of clinician-validated protocols, bloodwork reviews, and cycle audits. Not PubMed. Not Reddit.
Clinicians who run longevity-focused practices treat NAD+ administration as one of the most-debated compounds in current practitioner discussion. In protocol audits we've reviewed, two camps emerge: IV NAD+ enthusiasts citing rapid subjective response and the precursor (NMN/NR) camp citing oral convenience and theoretical bioavailability advantages. Subcutaneous NAD+ protocols sit between these poles. Practitioners universally recommend TMG (trimethylglycine) co-administration to support methyl donor pools depleted during NAD+ catabolism.
Dosing
100–500 mg subcutaneous; 250–1000 mg IV; precursor (NMN/NR) protocols 250–1000 mg oral
Subcutaneous, intramuscular, intravenous, intranasal, or oral precursor (NMN, NR). IV protocols typically delivered over 1–4 hours.
Cycle
Common practitioner pattern: loading phase of 5–10 IV sessions over 2–4 weeks, then weekly or biweekly maintenance. Subcutaneous protocols often run 3–5 days/week. Oral precursor protocols are typically continuous.
Evidence Breakdown
Every finding about NAD+is categorized across three independent evidence lanes. You always know what research tier you’re acting on.
- Limited human trials of exogenous NAD+ administration; precursor (NMN, NR) clinical research is more developed but outcomes are modest in published data.
- Strong practitioner interest, particularly in IV and subcutaneous protocols. Methylation co-administration (TMG) is near-universal in audited longevity protocols.
- Emerging research investigates NAD+ in mitochondrial dysfunction, neurodegenerative-disease research, and broad longevity applications. Cellular pool dynamics remain an active research area.
Cycling & Stack Considerations
Cycling Protocol
Common practitioner pattern: loading phase of 5–10 IV sessions over 2–4 weeks, then weekly or biweekly maintenance. Subcutaneous protocols often run 3–5 days/week. Oral precursor protocols are typically continuous.
Common Stacks
- •NAD+ + TMG (methylation support during NAD+ catabolism)
- •NAD+ + GHK-Cu (longevity research stack)
- •NAD+ + Epitalon (longevity research stack)
Interactions & Overlap
- •NMN, NR, and other NAD+ precursors (mechanistically overlapping; choice between forms is the practitioner question)
- •Methylation-supportive compounds (TMG often co-administered to support methyl donor pools)
- •Stimulants (some practitioner reports suggest synergistic alertness research effects)
Honest negatives · the part other trackers skip
Contraindications & Watch-Outs
Research Watch-Outs
- Active malignancy — NAD+ supports cellular metabolism broadly; practitioner consultation required
- Pregnancy and lactation — limited safety data
- IV protocol: cardiovascular contraindications to rapid IV infusion (chest pressure during infusion is common and rate-dependent)
NAD+ FAQs
What is the half-life of NAD+?
Plasma half-life of IV NAD+ is short (minutes-scale). Cellular NAD+ pool turnover operates on a hours-to-days timescale and depends on tissue, baseline status, and concurrent precursor intake.
NAD+ vs NMN vs NR — which is better?
NAD+ administration provides the coenzyme directly; NMN and NR are precursors that the body converts to NAD+. Practitioner debate continues; NMN and NR have stronger oral bioavailability research, while IV/SC NAD+ enthusiasts cite faster subjective response.
What is the typical NAD+ dose?
Subcutaneous: 100–500 mg per session. IV: 250–1000 mg delivered over 1–4 hours. Oral precursors (NMN, NR): 250–1000 mg daily. Loading-then-maintenance protocols are common across all routes.
Why does IV NAD+ cause chest pressure?
Chest pressure or tightness during IV NAD+ infusion is rate-dependent and commonly reported. Slowing the infusion rate typically resolves the sensation. Practitioners adjust delivery rate based on individual tolerance.
Should TMG be taken with NAD+?
Yes — TMG (trimethylglycine) co-administration is near-universal in practitioner protocols. NAD+ catabolism produces methylated nicotinamide metabolites; TMG supports the methyl donor pool used in this process.
How often should NAD+ be administered?
Loading protocols use 5–10 IV sessions over 2–4 weeks. Maintenance is typically weekly or biweekly. Subcutaneous protocols often run 3–5 days/week. Oral precursor protocols are typically continuous.
Is NAD+ FDA approved?
NAD+ and its precursors are not FDA approved as drugs for any specific indication. They are sold as research compounds and dietary supplements depending on form.
Related Compounds
Track your NAD+ protocol in DoseCraft
The PK-aware protocol builder models Variable (minutes for IV NAD+; hours for precursors) decay, checks stack overlap, and flags contraindications — built on the same practitioner corpus that powers this page.
See pricingFor research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Content on this page is educational and does not constitute medical advice, dosing guidance, or a protocol recommendation. Consult a qualified clinician before undertaking any research involving peptide compounds.